G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer

Christina Y. Yim, Emmanuel Bikorimana, Ema Khan, Joshua M. Warzecha, Leah Shin, Jennifer Rodriguez, Ethan Dmitrovsky, Sarah J. Freemantle, Michael J. Spinella

Research output: Contribution to journalArticle

Abstract

G0/G1 switch gene 2 (G0S2) is a direct retinoic acid target implicated in cancer biology and therapy based on frequent methylation-mediated silencing in diverse solid tumors. We recently reported that low G0S2 expression in breast cancer, particularly estrogen receptor-positive (ER+) breast cancer, correlates with increased rates of recurrence, indicating that G0S2 plays a role in breast cancer progression. However, the function(s) and mechanism(s) of G0S2 tumor suppression remain unclear. In order to determine potential mechanisms of G0S2 anti-oncogenic activity, we performed genome-wide expression analysis that revealed an enrichment of gene signatures related to PI3K/mTOR pathway activation in G0S2 null cells as compared to G0S2 wild-type cells. G0S2 null cells also exhibited a dramatic decreased sensitivity to PI3K/mTOR pathway inhibitors. Conversely, restoring G0S2 expression in human ER+ breast cancer cells decreased basal mTOR signaling and sensitized the cells to pharmacologic mTOR pathway inhibitors. Notably, we provide evidence here that the increase in recurrence seen with low G0S2 expression is especially prominent in patients who have undergone antiestrogen therapy. Further, ER+ breast cancer cells with restored G0S2 expression had a relative increased sensitivity to tamoxifen. These findings reveal that in breast cancer G0S2 functions as a tumor suppressor in part by repressing PI3K/mTOR activity, and that G0S2 enhances therapeutic responses to PI3K/mTOR inhibitors. Recent studies implicate hyperactivation of PI3K/mTOR signaling as promoting resistance to antiestrogen therapies in ER+ breast cancer. Our data establishes G0S2 as opposing this form of antiestrogen resistance. This promotes further investigation of the role of G0S2 as an antineoplastic breast cancer target and a biomarker for recurrence and therapy response.

Original languageEnglish (US)
Pages (from-to)2146-2155
Number of pages10
JournalCell Cycle
Volume16
Issue number21
DOIs
StatePublished - Nov 2 2017

Fingerprint

Switch Genes
Phosphatidylinositol 3-Kinases
Breast Neoplasms
Estrogen Receptor Modulators
Gene Expression
Null Lymphocytes
Recurrence
Neoplasms
Therapeutics

Keywords

  • Breast cancer
  • PI3K
  • estrogen receptor
  • mTOR
  • recurrence

ASJC Scopus subject areas

  • Molecular Biology
  • Developmental Biology
  • Cell Biology

Cite this

G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer. / Yim, Christina Y.; Bikorimana, Emmanuel; Khan, Ema; Warzecha, Joshua M.; Shin, Leah; Rodriguez, Jennifer; Dmitrovsky, Ethan; Freemantle, Sarah J.; Spinella, Michael J.

In: Cell Cycle, Vol. 16, No. 21, 02.11.2017, p. 2146-2155.

Research output: Contribution to journalArticle

Yim, Christina Y. ; Bikorimana, Emmanuel ; Khan, Ema ; Warzecha, Joshua M. ; Shin, Leah ; Rodriguez, Jennifer ; Dmitrovsky, Ethan ; Freemantle, Sarah J. ; Spinella, Michael J. / G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer. In: Cell Cycle. 2017 ; Vol. 16, No. 21. pp. 2146-2155.
@article{ba9c46fafa204dad9c66a72434e2b413,
title = "G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer",
abstract = "G0/G1 switch gene 2 (G0S2) is a direct retinoic acid target implicated in cancer biology and therapy based on frequent methylation-mediated silencing in diverse solid tumors. We recently reported that low G0S2 expression in breast cancer, particularly estrogen receptor-positive (ER+) breast cancer, correlates with increased rates of recurrence, indicating that G0S2 plays a role in breast cancer progression. However, the function(s) and mechanism(s) of G0S2 tumor suppression remain unclear. In order to determine potential mechanisms of G0S2 anti-oncogenic activity, we performed genome-wide expression analysis that revealed an enrichment of gene signatures related to PI3K/mTOR pathway activation in G0S2 null cells as compared to G0S2 wild-type cells. G0S2 null cells also exhibited a dramatic decreased sensitivity to PI3K/mTOR pathway inhibitors. Conversely, restoring G0S2 expression in human ER+ breast cancer cells decreased basal mTOR signaling and sensitized the cells to pharmacologic mTOR pathway inhibitors. Notably, we provide evidence here that the increase in recurrence seen with low G0S2 expression is especially prominent in patients who have undergone antiestrogen therapy. Further, ER+ breast cancer cells with restored G0S2 expression had a relative increased sensitivity to tamoxifen. These findings reveal that in breast cancer G0S2 functions as a tumor suppressor in part by repressing PI3K/mTOR activity, and that G0S2 enhances therapeutic responses to PI3K/mTOR inhibitors. Recent studies implicate hyperactivation of PI3K/mTOR signaling as promoting resistance to antiestrogen therapies in ER+ breast cancer. Our data establishes G0S2 as opposing this form of antiestrogen resistance. This promotes further investigation of the role of G0S2 as an antineoplastic breast cancer target and a biomarker for recurrence and therapy response.",
keywords = "Breast cancer, PI3K, estrogen receptor, mTOR, recurrence",
author = "Yim, {Christina Y.} and Emmanuel Bikorimana and Ema Khan and Warzecha, {Joshua M.} and Leah Shin and Jennifer Rodriguez and Ethan Dmitrovsky and Freemantle, {Sarah J.} and Spinella, {Michael J.}",
year = "2017",
month = "11",
day = "2",
doi = "10.1080/15384101.2017.1371884",
language = "English (US)",
volume = "16",
pages = "2146--2155",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "21",

}

TY - JOUR

T1 - G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer

AU - Yim, Christina Y.

AU - Bikorimana, Emmanuel

AU - Khan, Ema

AU - Warzecha, Joshua M.

AU - Shin, Leah

AU - Rodriguez, Jennifer

AU - Dmitrovsky, Ethan

AU - Freemantle, Sarah J.

AU - Spinella, Michael J.

PY - 2017/11/2

Y1 - 2017/11/2

N2 - G0/G1 switch gene 2 (G0S2) is a direct retinoic acid target implicated in cancer biology and therapy based on frequent methylation-mediated silencing in diverse solid tumors. We recently reported that low G0S2 expression in breast cancer, particularly estrogen receptor-positive (ER+) breast cancer, correlates with increased rates of recurrence, indicating that G0S2 plays a role in breast cancer progression. However, the function(s) and mechanism(s) of G0S2 tumor suppression remain unclear. In order to determine potential mechanisms of G0S2 anti-oncogenic activity, we performed genome-wide expression analysis that revealed an enrichment of gene signatures related to PI3K/mTOR pathway activation in G0S2 null cells as compared to G0S2 wild-type cells. G0S2 null cells also exhibited a dramatic decreased sensitivity to PI3K/mTOR pathway inhibitors. Conversely, restoring G0S2 expression in human ER+ breast cancer cells decreased basal mTOR signaling and sensitized the cells to pharmacologic mTOR pathway inhibitors. Notably, we provide evidence here that the increase in recurrence seen with low G0S2 expression is especially prominent in patients who have undergone antiestrogen therapy. Further, ER+ breast cancer cells with restored G0S2 expression had a relative increased sensitivity to tamoxifen. These findings reveal that in breast cancer G0S2 functions as a tumor suppressor in part by repressing PI3K/mTOR activity, and that G0S2 enhances therapeutic responses to PI3K/mTOR inhibitors. Recent studies implicate hyperactivation of PI3K/mTOR signaling as promoting resistance to antiestrogen therapies in ER+ breast cancer. Our data establishes G0S2 as opposing this form of antiestrogen resistance. This promotes further investigation of the role of G0S2 as an antineoplastic breast cancer target and a biomarker for recurrence and therapy response.

AB - G0/G1 switch gene 2 (G0S2) is a direct retinoic acid target implicated in cancer biology and therapy based on frequent methylation-mediated silencing in diverse solid tumors. We recently reported that low G0S2 expression in breast cancer, particularly estrogen receptor-positive (ER+) breast cancer, correlates with increased rates of recurrence, indicating that G0S2 plays a role in breast cancer progression. However, the function(s) and mechanism(s) of G0S2 tumor suppression remain unclear. In order to determine potential mechanisms of G0S2 anti-oncogenic activity, we performed genome-wide expression analysis that revealed an enrichment of gene signatures related to PI3K/mTOR pathway activation in G0S2 null cells as compared to G0S2 wild-type cells. G0S2 null cells also exhibited a dramatic decreased sensitivity to PI3K/mTOR pathway inhibitors. Conversely, restoring G0S2 expression in human ER+ breast cancer cells decreased basal mTOR signaling and sensitized the cells to pharmacologic mTOR pathway inhibitors. Notably, we provide evidence here that the increase in recurrence seen with low G0S2 expression is especially prominent in patients who have undergone antiestrogen therapy. Further, ER+ breast cancer cells with restored G0S2 expression had a relative increased sensitivity to tamoxifen. These findings reveal that in breast cancer G0S2 functions as a tumor suppressor in part by repressing PI3K/mTOR activity, and that G0S2 enhances therapeutic responses to PI3K/mTOR inhibitors. Recent studies implicate hyperactivation of PI3K/mTOR signaling as promoting resistance to antiestrogen therapies in ER+ breast cancer. Our data establishes G0S2 as opposing this form of antiestrogen resistance. This promotes further investigation of the role of G0S2 as an antineoplastic breast cancer target and a biomarker for recurrence and therapy response.

KW - Breast cancer

KW - PI3K

KW - estrogen receptor

KW - mTOR

KW - recurrence

UR - http://www.scopus.com/inward/record.url?scp=85029474752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029474752&partnerID=8YFLogxK

U2 - 10.1080/15384101.2017.1371884

DO - 10.1080/15384101.2017.1371884

M3 - Article

C2 - 28910567

AN - SCOPUS:85029474752

VL - 16

SP - 2146

EP - 2155

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 21

ER -